At Aarvik, we believe improving clinical efficacy and lowering the minimum efficacious dose (MED), while maintaining or improving the maximum tolerated dose (MTD), is a powerful approach to increasing the therapeutic index of ADCs.
Our unique and comprehensive MUTTA™ ADC platform can unlock a large number of tumor antigen targets with low copy numbers, unsuccessfully pursued so far.